JP2020516601A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516601A5
JP2020516601A5 JP2019554737A JP2019554737A JP2020516601A5 JP 2020516601 A5 JP2020516601 A5 JP 2020516601A5 JP 2019554737 A JP2019554737 A JP 2019554737A JP 2019554737 A JP2019554737 A JP 2019554737A JP 2020516601 A5 JP2020516601 A5 JP 2020516601A5
Authority
JP
Japan
Prior art keywords
antigen
tumor
protein
arenavirus
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019554737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516601A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/058900 external-priority patent/WO2018185307A1/en
Publication of JP2020516601A publication Critical patent/JP2020516601A/ja
Publication of JP2020516601A5 publication Critical patent/JP2020516601A5/ja
Pending legal-status Critical Current

Links

JP2019554737A 2017-04-07 2018-04-06 固形腫瘍を治療するためのアレナウイルス粒子 Pending JP2020516601A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762483067P 2017-04-07 2017-04-07
US62/483,067 2017-04-07
PCT/EP2018/058900 WO2018185307A1 (en) 2017-04-07 2018-04-06 Arenavirus particles to treat solid tumors

Publications (2)

Publication Number Publication Date
JP2020516601A JP2020516601A (ja) 2020-06-11
JP2020516601A5 true JP2020516601A5 (https=) 2021-05-20

Family

ID=62025795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019554737A Pending JP2020516601A (ja) 2017-04-07 2018-04-06 固形腫瘍を治療するためのアレナウイルス粒子

Country Status (7)

Country Link
US (1) US20200113995A1 (https=)
EP (1) EP3606549A1 (https=)
JP (1) JP2020516601A (https=)
CN (1) CN110719788A (https=)
AU (1) AU2018247958A1 (https=)
CA (1) CA3058539A1 (https=)
WO (1) WO2018185307A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
CN115058452A (zh) 2013-12-03 2022-09-16 霍欧奇帕生物科技有限公司 Cmv疫苗
LT3218504T (lt) 2014-11-13 2020-09-10 Université De Geneve Trijų segmentų arenavirusai kaip vakcinos vektoriai
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
IL314371A (en) 2015-11-04 2024-09-01 Hookipa Biotech Gmbh Vaccines against hepatitis B virus
RS63546B1 (sr) 2015-11-12 2022-09-30 Hookipa Biotech Gmbh Čestice arenavirusa kao vakcine protiv kancera
MX2022014725A (es) * 2020-05-29 2023-02-09 Hookipa Biotech Gmbh Estrategias de tratamiento del cáncer mediante el uso de vectores de arenavirus.
CN117280027A (zh) 2021-03-23 2023-12-22 霍欧奇帕生物科技有限公司 用于治疗前列腺癌的沙粒病毒
US20240229073A1 (en) * 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
CA3236106A1 (en) 2021-11-08 2023-05-11 Henning Lauterbach Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
TW202346363A (zh) * 2022-03-16 2023-12-01 德商百靈佳殷格翰國際股份有限公司 腫瘤抗原、包含所述腫瘤抗原的化合物及其用途
CN115192709B (zh) * 2022-05-12 2023-07-21 黄淮学院 O-GlcNAc糖基转移酶抑制剂在制备抑制精子发生的药物中的用途
CN116218681B (zh) * 2022-08-02 2025-11-11 汕头大学 三角褐指藻钙网蛋白基因过表达突变株的构建方法
WO2025101837A1 (en) * 2023-11-10 2025-05-15 Eccletech Llc Biological devices and methods of using the same for detection of different types of cancer
WO2025191169A1 (en) 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
MXPA05003395A (es) * 2002-10-03 2005-06-22 Wyeth Corp Polipeptidos de virus de papiloma humano y composiciones inmunogenas.
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP2604695B1 (en) * 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
EP2968506B1 (en) 2013-03-15 2019-07-31 Université de Genève Anti-mycobacterial vaccines
WO2015127501A1 (en) * 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
LT3218504T (lt) 2014-11-13 2020-09-10 Université De Geneve Trijų segmentų arenavirusai kaip vakcinos vektoriai
DE102015207036A1 (de) * 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
RU2749113C2 (ru) * 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
EP3307308A2 (en) * 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
RS63546B1 (sr) * 2015-11-12 2022-09-30 Hookipa Biotech Gmbh Čestice arenavirusa kao vakcine protiv kancera
US20190135875A1 (en) 2016-05-18 2019-05-09 Hookipa Biotech Gmbh Tri-segmented pichinde viruses as vaccine vectors
EP3534943A2 (en) * 2016-11-04 2019-09-11 Hookipa Biotech GmbH Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines

Similar Documents

Publication Publication Date Title
JP2020516601A5 (https=)
JP2018533604A5 (https=)
JP2019533690A5 (https=)
HRP20221167T1 (hr) Čestice arenavirusa kao cjepiva protiv raka
JP2023029898A5 (https=)
Rühl et al. Vaccination against the Epstein–Barr virus
Flingai et al. Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants
JP2010533649A5 (https=)
US20220380805A1 (en) Arenaviruses as vectors
WO2018185307A1 (en) Arenavirus particles to treat solid tumors
US20180237477A1 (en) Polynucleotides for treating oncogenic viral polypeptide positive tumors
BR112020003007A2 (pt) modificação de células t
US20190000943A1 (en) Aav6 vectors for immunotherapy
JPWO2021089853A5 (https=)
KR20260012231A (ko) 백신접종용 항원-특이적 생리학적 수지상 세포
Cubillos-Zapata et al. Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo
Wang et al. Development of a novel PCV2 and PCV3 vaccine using virus-like vesicles incorporating Venezuelan equine encephalomyelitis virus-containing vesicular stomatitis virus glycoprotein
Sherritt et al. Effect of pre‐existing cytotoxic T lymphocytes on therapeutic vaccines
AR132582A1 (es) Método para inducir una respuesta inmunitaria
WO2011056993A1 (en) Compositions and methods for treating cancer with attenuated oncolytic viruses
US20140286978A1 (en) Cytotoxic t lymphocyte inducer
US20240245765A1 (en) Use of Ectromelia Virus for Cancer Immunotherapy and Vaccines
Rossiter Attempts to protect rabbits against challenge with virulent, cell-associated, malignant catarrhal fever virus
KR20260010716A (ko) 요법용 항원-특이적 생리학적 수지상 세포
Böhm et al. DNA-Based Vaccination Primes Tumor-Rejecting T-Cell Responses